David A. Siegel Mersana Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 448,000 shares of MRSN stock, worth $206,080. This represents 0.0% of its overall portfolio holdings.
Number of Shares
448,000
Previous 486,800
7.97%
Holding current value
$206,080
Previous $920,000
30.43%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding MRSN
# of Institutions
136Shares Held
101MCall Options Held
77.2KPut Options Held
453K-
Nextech Invest Ag12.1MShares$5.55 Million3.22% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$5.21 Million0.76% of portfolio
-
Vr Adviser, LLC New York, NY10.3MShares$4.72 Million2.42% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$3.99 Million3.35% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$3.86 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $44.7M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...